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Abstract 
 
Background: Alpha-1-acid glycoprotein (AGP), an inflammatory marker, was found to have the strongest 
association with 5-year mortality in a recent study that examined 106 biomarkers. Our objective was to 
examine whether it is a better marker of mortality risk than more commonly used inflammatory biomarkers 
C-reactive protein (CRP) and interleukin-6 (IL-6). 
 
Methods: We analyzed data on 6545 men and women aged 45-69 (mean 55.7) years from the Whitehall II 
cohort study. Biomarkers (AGP, CRP, and IL-6) were assayed from fasting serum collected in 1997-1999. 
Mortality follow-up was until June, 2015. Cox regression was used to model associations of inflammatory 
markers with all-cause, cancer, and cardiovascular mortality.  
 
Results: Over the mean follow-up of 16.7 years, 736 deaths occurred, of which 181 were from 
cardiovascular disease and 347 from cancer. In models adjusted for age, sex, BMI, health behaviors and 
chronic disease (prevalent coronary heart disease, type 2 diabetes, any cancer type and chronic obstructive 
pulmonary disease), AGP did not predict mortality beyond the first 5 years of follow-up, over this period IL-
6 and CRP had stronger associations with mortality. When considering all covariates and biomarkers 
simultaneously, AGP no longer predicted all-cause mortality (HR=0.99, 95% CI 0.90-1.08). Only IL-6 
predicted all-cause (HR=1.22, 95% CI: 1.12-1.33) and cancer mortality (HR=1.13, 95% CI: 1.00-1.29) over the 
entire follow-up, while CRP predicted only cardiovascular mortality (HR=1.30, 95% CI: 1.06-1.61). 
 
Interpretation: Our analyses suggest alpha-1-acid glycoprotein is not a better marker of short- or long-term 
mortality risk than commonly used interleukin-6 and C-reactive protein. 
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Inflammatory biomarkers are useful indicators of infection in care settings(1) and have great value for 
monitoring chronic disease activity(2) and overall health status in the wider population.(3) Considerable 
research shows inflammatory markers to predict mortality in adults with chronic conditions such as type 2 
diabetes(4) and cardiovascular disease,(5) while interleukin-6 (IL-6) and C-reactive protein (CRP) have also 
been shown to predict mortality and cardiovascular outcomes in general population settings.(6) In older 
adults, IL-6 appears to have a stronger association than CRP with all-cause mortality.(3) For cardiovascular 
outcomes, Mendelian randomization studies suggest causal effects for IL-6 but not CRP.(7, 8) 
 
A recent metabolomics study examined 106 biomarkers and found alpha-1-acid glycoprotein (AGP), an 
acute phase protein, to be the strongest predictor of five-year mortality.(9) The importance of this finding 
has not been established for mortality follow-up beyond five years. It is also unknown how well AGP 
compares with other sensitive, dynamic, and commonly measured markers of systemic inflammation, such 
as CRP and IL-6, as a predictor of mortality. To address this question, we compared associations of these 
three inflammatory markers with short- and long-term risk of all-cause, cardiovascular- and cancer-related 
mortality in a large cohort study. We also examined absolute differences in life expectancy at age 50 in 
those with high versus low inflammation based on each marker. 
 
Methods 
The Whitehall II study is a cohort study of men and women originally employed by the British civil service in 
London-based offices. (10) A total of 10,308 persons (6895 men and 3413 women, aged 35-55) were 
recruited to the study over the years 1985 to 1988, with a response rate of 73%.(9) Since the baseline 
medical examination, follow-up examinations have taken place approximately every 5 years. Ethical 
approval was obtained from the University College London Medical School committee on the ethics of 
human research (reference number 85/0938); all participants provided written informed consent. 
 
Assessment of IL-6, CRP, and AGP 
Samples of fasting serum for inflammatory markers were collected in 1997-1999. CRP was measured with a 
high-sensitivity immunonephelometric assay in a BN ProSpec nephelometer (Dade Behring, Milton Keynes, 
UK); IL-6 with a high-sensitivity ELISA (R&D Systems, Oxford, UK); and AGP using nuclear magnetic 
resonance spectroscopy as part of more complete biomarker profiling.(11) 
 
Mortality  
Mortality data until June 2015 were drawn from the British national mortality register (National Health 
Services Central Registry). The tracing exercise was carried out using the National Health Service 
identification number of each participant. Besides all-cause mortality, the 9th and 10th revisions of the 
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International Classification of Disease were used to examine deaths due to cardiovascular-- (ICD-9 codes 
390–459 and ICD-10 codes I00-I99) and cancer- (ICD-9 codes 140–208 and ICD-10 codes C00-C97) related 
causes. 
 
Covariates  
Covariates used in the analyses were drawn from the 1997-1999 assessment, concurrent to the 
measurement of inflammatory markers. Demographic covariates included age, sex, and employment grade 
– a 3-level marker of socioeconomic status (SES) in the Whitehall II study.(10) Health behavior covariates 
included smoking status (categorized as current, ex-, and never smoker), alcohol consumption (assessed via 
questions on the number of alcoholic drinks consumed in the last week and converted to units of alcohol), 
physical activity level (defined as ‘active’ for ≥2.5 hours/week of moderate physical activity or ≥1 
hour/week of vigorous physical activity, ‘inactive’ for <1 hour/week of moderate and vigorous activity and 
‘intermediate’ for all others), and dietary behavior (assessed using a question on frequency of fruit and 
vegetable consumption in a typical week). Body mass-index (BMI) was measured as weight, 
kilograms/height in metres2 and used as a continuous variable. Chronic disease burden was assessed by 
prevalence of coronary heart disease (CHD) and stroke (CHD included definite non-fatal myocardial 
infarction and definite angina cases based on questionnaires, study electrocardiograms, and use of cardiac 
enzymes; stroke was self-reported; as far as possible, all identified cases were corroborated via linkage to 
the UK Hospital Episode Statistics database which contains data on all in- and out-patient treatment); 
chronic obstructive pulmonary disease (MRC respiratory questionnaire(12) self-reported), cancer (assessed 
using the National Health Service cancer registry); and type 2 diabetes mellitus (determined by fasting 
glucose ≥ 7.0 mmol/l and/or 2-h postload glucose ≥ 11.1 mmol/l, self-report of doctor diagnosis or diabetes 
medication).(13)  
 
Statistical analyses 
We examined participants’ baseline characteristics as a function of vital status at the end of follow-up and 
summarized the associations using standardized differences. Inflammatory markers were log-transformed 
owing to skewed distributions and standardized to z-scores to allow comparison of effect sizes. 590 
individuals (9.0%) had missing values for one or more variables which were imputed using multiple 
imputation to generate ten datasets which were analyzed separately with the results being combined using 
Rubin’s rules.(14)  
 
For survival analyses, participants were followed until death or until the date of censoring for those who 
were alive (date of emigration or June 30th, 2015), whichever occurred first. Cox proportional hazards 
models with years of follow-up as the underlying time variable were used to examine hazard ratios (HR) 
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and their 95% confidence intervals (CI) for associations with mortality. Schoenfeld’s residuals suggested 
violation of the proportionality of hazards assumption, justifying our use of three follow-up periods for 
mortality outcomes: 0-5y, 5-10y, ≥10y. There were no sex differences in associations between 
inflammatory markers and mortality, p for interaction ranged from 0.16 to 0.42, leading us to combine men 
and women in analyses. The first model adjusted for age and sex (Model 1). The second model additionally 
adjusted for SES, BMI, health behaviors, and prevalent chronic disease (Model 2). The final model included 
all three inflammatory markers along with covariates (Model 3). 
 
In order to take into account possible threshold effects, analyses with mortality were repeated using 
tertiles for each inflammatory marker (comparing highest versus lowest). Using these same tertiles, we 
estimated remaining life expectancy at age 50 for men and women with high versus low inflammation by 
multiplying the England and Wales age-specific mortality rates for 2011-2013 with the hazard ratios for the 
inflammatory marker-mortality association in the two groups compared with the total sample. These 
analyses were undertaken separately in men and women due to known sex differences in life expectancy.  
 
All analyses were undertaken using SAS 9.2 (SAS Institute, NC, USA). Statistical tests were 2-sided with a P-
value<0.05 considered statistically significant. 
 
 
Results 
A total of 6551 participants underwent clinical assessment in 1997-99, six of whom were not linked to 
mortality records and were excluded from all analyses. Mean (range) age of participants at the 1997-99 
clinical assessment was 55.7 (45-69) years. A total of 736 deaths occurred over a mean follow-up of 16.7 
years, 14.5% in the first five years, and 61.7% more than ten years after assessment of biomarkers. Those 
who died were older (59.6 vs 55.2 years) but did not differ by sex (Table 1). They had an adverse 
socioeconomic and disease profile, including higher levels of all three inflammatory markers (Table 1). AGP 
was correlated with IL-6 (r=0.29, p<0.001) and CRP (r=0.33, p<0.001); IL-6 and CRP were also correlated 
with each other (r=0.46, p<0.001). 
 
In models adjusted for age and sex (Model 1), all three inflammatory biomarkers were associated with all-
cause mortality (Table 2). In addition, all associations weakened over time and were stronger for deaths 
occurring in the first five years than for those occurring ≥10 years. In models adjusted for all covariates 
(Model 2), AGP did not predict mortality beyond the first five years of follow-up. In analyses considering all 
three biomarkers simultaneously (Model 3), only IL-6 predicted short- and long-term mortality from all 
causes, the overall hazard ratio for the entire follow-up being 1.22 (95% CI: 1.12, 1.33). Table 3 shows the 
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unadjusted and mutually adjusted associations of all covariates with all-cause mortality, the mutually 
adjusted model corresponded to Model 3 in Table 2 for inflammatory markers.  
 
A total of 181 (24.6%) deaths were attributed to cardiovascular disease, for which all three markers were 
significant predictors in models adjusted for age and sex (Model 1, Table 2), although the association with 
AGP was driven primarily by deaths in the first five years of follow-up (HR=1.43 for deaths in the first five 
years compared with 1.09 for deaths after 10 years, Table 2). In analyses adjusted for covariates and 
mutually adjusted for the three inflammatory markers (Model 3), only CRP remained associated with 
cardiovascular deaths (HR=1.30, 95% CI: 1.06, 1.61). This pattern was also observed in analyses stratified by 
duration of follow-up.   
 
Of the deaths, 47.1% were due to cancer. All three markers were associated with cancer deaths in models 
adjusted for age and sex (Model 1), although not beyond the first five years for AGP (Table 2). In the fully 
adjusted model including all three inflammatory markers (Model 3), only IL-6 was associated with cancer 
mortality (HR=1.13, 95% CI: 1.00, 1.29).  
 
In order to take into account possible threshold effects, mortality risk was compared in the top versus the 
bottom tertile of each inflammatory marker. As shown in Table 4, no association was observed between 
AGP and mortality in models adjusted for all covariates (Models 2 and 3). On the other hand, IL-6 was 
associated with all-cause mortality in all models, irrespective of the covariates included. 
 
Figure 1 shows remaining life expectancy at age 50 in participants with high compared with low 
inflammation, defined using the highest compared with the lowest tertile. For AGP, there was a non-
statistically significant difference in remaining life expectancy in men and women of 1.0 year (95% CI: 0.0, 
2.0), p=0.054 and 0.06 in men and women. The difference in remaining life expectancy at age 50 (Figure 1) 
was significantly lower in those in the highest tertile of IL-6 (3.8 years; 95% CI: 2.9, 4.7) and CRP (2.7 years; 
95% CI: 1.6, 3.7).  
 
 
Interpretation 
 
Main findings 
 
This analysis examined the association of three inflammatory markers with short- and long-term mortality 
in a large sample of middle-aged adults, followed for 17 years. Analyses were motivated by a recent 
molecular profiling study that assessed the association of 106 metabolites with mortality and found AGP to 
7 
 
have the strongest association with all-cause mortality.(9) As AGP is an acute phase protein which is not 
widely measured,(15) we compared its predictive ability with more commonly measured inflammatory 
markers for mortality. Our results show that AGP was indeed associated with all-cause and cancer mortality 
in the short term; however it was not associated with mortality in the longer term. Furthermore, when 
examining all three inflammatory markers in mutually adjusted models, AGP was not associated with 
mortality even in the short term. Thus, our analyses provide no evidence that AGP would be a better 
marker of mortality risk than more commonly used inflammatory indicators, IL-6 or CRP.  
 
In analysis adjusted for all covariates where each marker was examined separately, both CRP and IL-6 were 
associated with all-cause and cancer mortality over the 17-year follow-up, with CRP also associated with 
cardiovascular mortality. However, when all inflammatory markers were considered together, only IL-6 was 
associated with all-cause and cancer mortality and CRP with cardiovascular mortality. Identification of 
inexpensive prognostic markers for ill-health in vulnerable populations, the elderly, or those with chronic 
conditions is important for management of care, and a better understanding of the role of inflammatory 
markers in general population settings may help clarify their utility for guiding screening and prevention. 
Interactions between environmental, stochastic, genetic and epigenetic factors shape mortality risk. There 
is considerable interest in identifying biological markers of such risk, in particular those that can be 
measured non-invasively. Plasma biomarkers are ideal for this purpose although observed associations do 
not necessarily reflect causality. In our data, CRP outweighed IL-6 as a predictor of cardiovascular mortality 
although evidence from Mendelian randomization studies suggests a causal role for IL-6(16) but not 
CRP(17) in cardiovascular disease. Reanalysis of our data using tertiles of inflammatory markers rather than 
standardized z-scores suggested a robust association only between IL-6 and all-cause mortality. 
 
Plasma concentrations of acute phase proteins fluctuate in response to inflammation.  IL-6 is a major 
proinflammatory cytokine, produced in a variety of tissues, and CRP and AGP are downstream products of 
the acute phase response, derived via cytokine dependent hepatic biosynthesis and secretion into the 
systemic circulation.(18) Thus, IL-6 might be a more appropriate marker of long-term health status. There is 
considerable interest in the importance of inflammatory pathways for ageing outcomes.(19-21) It is 
possible that chronic low-grade inflammation plays a role in neurodegenerative diseases. This is supported 
by genome wide association studies showing a number of genetic variants that influence inflammatory 
pathways to be associated with development of Alzheimer’s disease.(22, 23)  
 
Comparison to previous studies 
 
In HIV-infected pregnant women, higher AGP is associated with increased risk of maternal death, postnatal 
transmission, and infant infection or death, possibly due to the impact of AGP on modulating immunity and 
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binding or carrying drugs.(1) There is little research on AGP and health status in general population 
samples, the exceptions being the study on metabolites and 5-year mortality where AGP was one of the 
106 biomarkers (no other inflammatory markers were examined in that study)(9) and those on mortality 
risk in healthy and hospitalized elderly.(24, 25) However, previous studies comparing AGP with other 
inflammatory markers for their associations with short- and long-term mortality are lacking. Our results 
show a robust association of AGP with 5-year risk of all-cause, cardiovascular and cancer mortality in 
analyses adjusted for age and sex, with the magnitude of effect being similar to previous reports.(9) 
However, by considering a longer follow-up and other inflammatory markers simultaneously, we showed 
that IL-6 and CRP are more important predictors of mortality, and that AGP does not provide additional 
information regarding mortality. 
 
Strengths and limitations 
 
A key strength of this study, compared to previous studies, is the extended follow-up for mortality in a large 
cohort of men and women. We were also able to examine cancer and cardiovascular mortality. Limitations 
of our study include the lack of ethnic diversity in the population. However, generalizability is unlikely to be 
compromised as the study was designed to include a wide socioeconomic spectrum, with over a 10-fold 
salary difference across the socioeconomic hierarchy. We have previously shown associations of common 
risk factors with CVD incidence in our study to be comparable to studies based on general population 
samples.(26)  A further limitation is the use of only three serum markers of systemic inflammation. CRP and 
IL-6 are widely used in clinical practice and CRP is particularly inexpensive to measure, although it remains 
unclear whether there exist more relevant markers of inflammation.  
 
Conclusions 
 
We found no evidence that AGP is a stronger prognostic marker of mortality than the widely used 
inflammatory markers, IL-6 and CRP. As with previous findings, AGP was associated with 5 year mortality 
but even with this length of follow-up it did not do better than IL-6 in predicting mortality. Our analysis of 
all-cause, cancer and cardiovascular mortality suggests that for all these outcomes IL-6 may be a better 
prognostic marker, both in the short and the long-term. 
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Table 1: Sample characteristics at start of follow-up (1997-1999) 
 Status at end of follow-up (06_ 2015) Standardized 
differe 
avencea 
 Alive (N=5809) Deceased (N=736) 
Characteristics in 1997-1999 
   
Age, Mean (SD) 55.2 (5.9) 59.6 (5.8)  0.75 
Men, % 70.9 71.1  0.00 
Low SES, % 13.2 17.9  0.13 
Current Smoker, % 9.0 16.1  0.22 
Units of alcohol consumption per week, Mean (SD) 13.6 (15.0) 14.8 (18.9)  0.07 
Inactive,b % 8.1 8.5 0.02 
Daily consumption of fruits & vegetables, % 73.8 69.7 -0.09 
BMI, Mean(SD) 26.1 (3.9) 26.7 (4.6)  0.16 
History of CVD (CHD or Stroke), % 5.4 13.2  0.27 
History of diabetes, % 5.6 12.5  0.24 
History of cancer, % 2.3 5.0  0.14 
History of COPD, % 7.5 11.9  0.15 
Inflammatory markers (standardized values),c Mean (SD) 
   Alpha-1-acid glycoprotein (AGP) -0.02 (0.99) 0.20 (1.05)  0.22 
   Interleukin-6 (IL-6) -0.05 (0.98) 0.42 (1.04)  0.47 
   C-reactive protein (CRP) -0.03 (0.99) 0.27 (1.03)  0.30 
SD: Standard Deviation 
a Standardized differences greater than 0.1 are considered meaningful  
b Inactive’ for <1 hour/week of moderate and vigorous activity 
c The median (inter quartile range) of each biomarker prior to standardization in the alive and deceased 
group are as follows: 
AGP: 1.42 (1.29, 1.57) and 1.47 (1.33, 1.62) 
IL-6: 1.38 (0.98, 2.04) and 1.84 (1.26, 2.82) 
CRP: 0.99 (0.50, 2.06) and 1.36 (0.64, 6.87) 
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Table 2: Associations of inflammatory biomarkers with all-cause, CVD and cancer mortalitya 
   Model 1 
Adjusted for age and sex 
Model 2 
Adjusted for age, sex, employment grade, BMI, 
health behaviors, and chronic disease 
Model 3 
Adjusted for all covariates and other 
inflammatory markers 
Follow
-up  
Deaths/
N 
AGP IL-6 CRP AGP IL-6 CRP AGP IL-6 CRP 
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
All-cause mortality 
ALL 736/6545 1.18 (1.09,1.27) 1.35 (1.26,1.44) 1.27 (1.17,1.37) 1.06 (0.97,1.15) 1.25 (1.16,1.35) 1.17 (1.07,1.27) 0.99 (0.90,1.08) 1.22 (1.12,1.33) 1.07 (0.97,1.18) 
0-5 y 107/6545 1.43 (1.19,1.72) 1.75 (1.49,2.06) 1.65 (1.36,2.00) 1.30 (1.06,1.59) 1.61 (1.36,1.92) 1.54 (1.25,1.90) 1.09 (0.87,1.37) 1.47 (1.20,1.81) 1.18 (0.93,1.51) 
5-10 y 175/6438 1.24 (1.08,1.44) 1.36 (1.18,1.56) 1.28 (1.10,1.50) 1.15 (0.98,1.34) 1.28 (1.10,1.49) 1.21 (1.02,1.43) 1.06 (0.89,1.27) 1.23 (1.04,1.46) 1.06 (0.87,1.30) 
≥10 y 454/6263 1.09 (0.99,1.20) 1.25 (1.14,1.37) 1.18 (1.08,1.31) 0.98 (0.88,1.09) 1.15 (1.04,1.27) 1.07 (0.96,1.20) 0.93 (0.83,1.05) 1.15(1.03,1.28) 1.04 (0.91,1.18) 
           
Cardiovascular mortalityb 
ALL 181/6541 1.27 (1.10,1.46) 1.37 (1.19,1.57) 1.51 (1.30,1.76) 1.06 (0.90,1.24) 1.19 (1.02,1.39) 1.32 (1.12,1.57) 0.94 (0.79,1.13) 1.08 (0.90,1.29) 1.30 (1.06,1.61) 
0-5 y 31/6543 1.44 (1.02,2.05) 1.57 (1.14,2.16) 1.56 (1.08,2.24) 1.28 (0.87,1.87) 1.34 (0.96,1.88) 1.49 (1.00,2.22) 1.11 (0.72,1.71) 1.17 (0.78,1.76) 1.28 (0.78,2.11) 
5-10 y 42/6436 1.32 (0.98,1.77) 1.51 (1.15,1.99) 1.63 (1.19,2.21) 1.06 (0.76,1.48) 1.36 (1.01,1.85) 1.39 (0.99,1.97) 0.92 (0.64,1.31) 1.25 (0.87,1.79) 1.28 (0.84,1.95) 
≥10 y 108/6263 1.20 (1.00,1.45) 1.26 (1.04,1.51) 1.45 (1.19,1.77) 0.99 (0.81,1.22) 1.07 (0.86,1.33) 1.25 (1.00,1.57) 0.91 (0.72,1.14) 0.97 (0.76,1.24) 1.32 (1.00,1.75) 
           
Cancer mortalityb 
ALL 347/6541 1.09 (0.98,1.22) 1.25 (1.13,1.39) 1.23 (1.11,1.38) 0.99 (0.88,1.12) 1.17 (1.04,1.30) 1.15 (1.02,1.30) 0.92 (0.81,1.06) 1.13(1.00,1.29) 1.12 (0.97,1.29) 
0-5 y 54/6543 1.50 (1.17,1.91) 1.66 (1.32,2.09) 1.78 (1.37,2.33) 1.35 (1.02,1.78) 1.52 (1.18,1.97) 1.64 (1.23,2.19) 1.13 (0.83,1.53) 1.30 (0.96,1.76) 1.34 (0.95,1.90) 
5-10 y 87/6436 1.11 (0.90,1.38) 1.21 (0.98,1.48) 1.17 (0.94,1.46) 1.01 (0.79,1.28) 1.11 (0.88,1.40) 1.07 (0.84,1.38) 0.97 (0.75,1.27) 1.09 (0.85,1.41) 1.04 (0.78,1.39) 
≥10 y 206/6263 0.99 (0.85,1.15) 1.17 (1.02,1.34) 1.14 (0.99,1.32) 0.90 (0.76,1.07) 1.10 (0.95,1.28) 1.08 (0.92,1.27) 0.85 (0.71,1.02) 1.10 (0.93,1.30) 1.10 (0.91,1.34) 
AGP: alpha-1-acid glycoprotein, IL-6: Interleukin-6, CRP: C-reactive protein (CRP). 
aHazard ratios (HR) are per 1-standard deviation increase in the inflammatory biomarker. 
b Four participants with unknown cause of death have been excluded from these analyses 
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Table 3: Hazard ratios for inflammatory biomarkers and baseline covariates for all-cause mortalitya 
 Unadjusted Mutually adjusted 
 HR (95% CI) HR (95% CI) 
Age, (per year) 1.12 (1.11, 1.14) 1.11 (1.10, 1.13) 
Sex, (Women vs Men) 0.98 (0.84, 1.15) 0.87 (0.72, 1.04) 
SES   
              Intermediate vs High 1.04 (0.89, 1.22) 0.98 (0.83, 1.16) 
                              Low vs High 1.41 (1.15, 1.73) 0.96 (0.75, 1.24) 
Smoking   
                Ex-smokers vs Never smokers 1.20 (1.03, 1.41) 1.07 (0.93, 1.30) 
       Current smokers vs Never smokers 2.08 (1.68, 2.56) 1.86 (1.49, 2.38) 
Alcohol consumption   
                           None vs Moderate 1.29 (1.06, 1.57) 1.12 (0.91, 1.38) 
                          Heavy vs Moderate 1.04 (0.88, 1.22) 1.10 (0.93, 1.30) 
Physical activity   
                       Inactive vs Active 1.08 (0.84, 1.41) 0.94 (0.72, 1.24) 
    Moderately active vs Active        1.24 (0.97, 1.59) 1.18 (0.91, 1.51) 
Fruit & vegetable consumption (≥ Daily vs < Daily) 0.82 (0.70, 0.96) 0.81 (0.69, 0.97) 
BMI, (per Kg/m2) 1.04 (1.02, 1.05) 1.01 (0.99, 1.03) 
History of CVD (CHD or Stroke), (Yes vs No) 2.45 (1.98, 3.04) 1.56 (1.25, 1.94) 
History of diabetes, (Yes vs No)  2.26 (1.82, 2.81) 1.61 (1.28, 2.01) 
History of cancer, (Yes vs No) 2.14 (1.54, 2.98) 1.86 (1.33, 2.60) 
History of COPD, (Yes vs No) 1.59 (1.26, 2.00) 1.20 (0.95, 1.52) 
Inflammatory markers, (per 1 SD)   
     Alpha-1-acid glycoprotein 1.23 (1.15, 1.32) 0.99 (0.90, 1.08) 
     Interleukin-6 1.48 (1.39, 1.58) 1.22 (1.12, 1.33) 
     C-reactive protein 1.33 (1.24, 1.43) 1.07 (0.97, 1.18) 
a All analyses based on 736 deaths among 6545 individuals  
SD: Standard Deviation 
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Table 4: Hazard ratios for the highest versus lowest tertile of inflammatory biomarkers for all-cause, CVD 
and cancer mortality over a mean follow-up of 16.7 years 
   AGP IL-6 CRP 
 Na No. 
deathsa 
HR (95% CI) HR (95% CI) HR (95% CI) 
Model 1: Adjusted for age and sex 
All-cause mortality 6545 736 1.43 (1.20, 1.65) 1.93 (1.58, 2.37) 1.52 (1.27, 1.83) 
CVD mortality 6541b 181 1.64 (1.11, 2.43) 1.96 (1.29, 2.99) 2.00 (1.35, 2.97) 
Cancer mortality 6541b 347 1.22 (0.94, 1.59) 1.56 (1.18, 2.08) 1.54 (1.18, 2.02) 
Model 2: Adjusted for age, sex, SES, BMI, health behaviors, and chronic disease 
All-cause mortality 6545 736 1.12 (0.92, 1.37) 1.58 (1.27, 1.96) 1.22 (0.99, 1.49) 
CVD mortality 6541b 181 1.08 (0.71, 1.63) 1.36 (0.86, 2.14) 1.36 (0.88, 2.10) 
Cancer mortality 6541b 347 0.96 (0.72, 1.27) 
1. 28 (0.94, 
1.73) 
1.29 (0.96, 1.73) 
Model 3: Adjusted for all covariates and other inflammatory markers 
All-cause mortality 6545 736 1.01 (0.82, 1.26) 1.53 (1.21, 1.93) 1.04 (0.83, 1.32) 
CVD mortality 6541b 181 0.94 (0.60, 1.47) 1.23 (0.76, 2.02) 1.27 (0.78, 2.08) 
Cancer mortality 6541b 347 0.85 (0.62, 1.15) 1.19 (0.86, 1.65) 1.29 (0.92, 1.81) 
AGP: alpha-1-acid glycoprotein, IL-6: Interleukin-6, CRP: C-reactive protein (CRP). 
a Numbers of participants and deaths in the analysis, including those in the middle tertile  
b Four participants with unknown cause of death have been excluded from these analyses 
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Figure 1: Life expectancy at age 50 in the lowest and highest tertile* of inflammatory biomarkers in 
men (Part A) and women (Part B) 
 
 
 
* The remaining years of life expectancy at age 50 in those in the lowest and highest tertile of each 
inflammatory biomarker, calculated using the mortality hazard ratio for each tertile compared with the total 
sample and applied to the England and Wales age-specific mortality rates for 2011-2013. 
The bars show 95% confidence limits. 
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